Cargando…

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

Detalles Bibliográficos
Autores principales:	Cui, W., Milner-Watts, C., Saith, S., Bhosle, J., Minchom, A.R., Davidson, M., Page, S., Locke, I., Yousaf, N., Popat, S., O'Brien, M.E.R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Association for the Study of Lung Cancer. Published by Elsevier Inc. Published by Elsevier Inc. 2021
Materias:	Advanced Nsclc
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997776/ http://dx.doi.org/10.1016/S1556-0864(21)02022-0

Ejemplares similares

182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study
por: Marin, E., et al.
Publicado: (2021)

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center
por: Pierre, C., et al.
Publicado: (2021)

Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
por: Joshi, Kroopa, et al.
Publicado: (2021)

1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
por: Joshi, K., et al.
Publicado: (2020)

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, W., et al.
Publicado: (2020)

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience
por: Cui, Wanyuan, et al.
Publicado: (2020)

The Peninsula stage III non-small cell lung cancer audit: assessing the impact of COVID-19 on treatment decisions
por: Smith, Philippa, et al.
Publicado: (2023)

A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma
por: Minchom, Anna, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications
por: Hindocha, Sumeet, et al.
Publicado: (2021)

Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
por: Tjong, Michael C., et al.
Publicado: (2021)

Crizotinib治疗ALK阳性伴骨髓转移的肺腺癌1例及文献复习
Publicado: (2015)

EML4-ALK融合基因阳性肺腺癌合并淋巴瘤1例并文献复习
Publicado: (2015)

非小细胞肺癌患者EML4-ALK融合基因突变研究
Publicado: (2015)

ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施
Publicado: (2015)

初露端倪——演绎ALK阳性非小细胞肺癌的中国故事
Publicado: (2015)

增强免疫组化和原位杂交方法检测非小细胞肺癌的ALK重排的临床可行性
Publicado: (2015)

ALK阳性非小细胞肺癌的诊断
Publicado: (2015)

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
por: Coker, Elizabeth A., et al.
Publicado: (2022)

A newly discovered member of the Atlastin family, BmAtlastin-n, has an antiviral effect against BmNPV in Bombyx mori
por: Liu, Tai-hang, et al.
Publicado: (2016)

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
por: Minchom, Anna, et al.
Publicado: (2017)

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity
por: Minchom, A R, et al.
Publicado: (2014)

Grading reflective essays: the reliability of a newly developed tool- GRE-9
por: Makarem, Nisrine N., et al.
Publicado: (2020)

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
por: Li, Changhui, et al.
Publicado: (2021)

Interaction of Destruxin A with Three Silkworm Proteins: BmCRT, BmDPP3, and BmPDIA5
por: Yin, Xuyu, et al.
Publicado: (2022)

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020)

Shape coexistence in $^{180}$Hg studied through the $\beta$ decay of $^{180}$Tl
por: Elseviers, J, et al.
Publicado: (2011)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Local for advanced, is this a paradox?
por: Bungaro, Maristella, et al.
Publicado: (2021)

Oligometastatic non-small cell lung cancer: from biology to clinical practice
por: Infante, Maurizio V., et al.
Publicado: (2021)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

Knockdown of BmTCP-1β Delays BmNPV Infection in vitro
por: Wang, Xue-yang, et al.
Publicado: (2019)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
por: Hutchings, Martin, et al.
Publicado: (2022)

BmREEPa Is a Novel Gene that Facilitates BmNPV Entry into Silkworm Cells
por: Dong, Xiao-long, et al.
Publicado: (2015)

Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy
por: Castagnoli, Francesca, et al.
Publicado: (2022)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
por: Xu, Ziyi, et al.
Publicado: (2023)

Naomi Richman, BM, FRCPsych
por: Graham, Philip
Publicado: (2019)

BM1: Events Guide
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_epl0ehunagi2h7jqng3gal97ea